ArticleAntimicrobial agents and chemotherapy2016
Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Pharmacokinetic/pharmacodynamic target attainment of eravacycline in a liver transplant recipient with refractory VREAntimicrobial agents and chemotherapy · 2026Article
- Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model ofMicrobiology spectrum · 2026Article
- Quantitative performance of humanized serum and epithelial lining fluid exposures of tigecycline and levofloxacin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model.The Journal of antimicrobial chemotherapy · 2024Article
- Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative.Antimicrobial agents and chemotherapy · 2020Article
- Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models.Antimicrobial agents and chemotherapy · 2020Article
- Eravacycline, a newly approved fluorocycline.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Review
- Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline.Clinical pharmacokinetics · 2019Review
- High-Precision Control of Plasma Drug Levels Using Feedback-Controlled Dosing.ACS pharmacology & translational science · 2018Article
- Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.Antimicrobial agents and chemotherapy · 2018Article
- Nonlinear Protein Binding: Not What You Think.Journal of pharmaceutical sciences · 2018Review
- Article
- Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.Antimicrobial agents and chemotherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed the pharmacokinetic profile of eravacycline, a novel antibiotic of the tetracycline class, and determined the dose in an immunocompetent murine thigh infection model that would provide free-drug exposure similar to that observed in humans after the administration of 1 mg/kg intravenously (i.v.) every 12 h (q12h). Eravacycline demonstrated a nonlinear protein-binding profile. The 2.5-mg/kg i.v. q12h dose in mice resulted in an area under the concentration-time curve for the free, unbound fraction of the drug of 1.64 mg · h/liter, which closely resembles the human exposure level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.